GreenLight agrees to field station in Spain to boost research and development for key plant health projects

Rhea-AI Summary

GreenLight Biosciences has announced its agreement to operate a field research station in Spain, enhancing its research capabilities in agriculture. Located near Seville, the site will facilitate field trials for addressing crop issues such as powdery mildew and the Colorado potato beetle. The company plans to lease 10 to 20 hectares, allowing for broad-spectrum testing and efficient field work. GreenLight aims to utilize this site to advance its portfolio in both plant health and external compound integration, reinforcing its commitment to addressing agricultural challenges.

Positive

• Establishment of a research station in Spain enhances agricultural research capabilities.
• The site will support testing against crucial agricultural issues, improving product development efficiency.
• Ability to conduct field trials more efficiently by leasing 10 to 20 hectares.

Negative

• None.

BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences, a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced its agreement to operate a field research station in Spain.

Located south of Seville, a key agricultural area with intensive year-round production, the farmland will allow GreenLight to accelerate its transition of research and discovery compounds into the field.

“The versatility of this site and its climate will enable us to conduct broad-spectrum testing for GreenLight’s emerging portfolio and support key projects, whether it’s plant diseases or insects,” says Andreas Hopf, VP of Plant Health Product Development.

GreenLight intends to lease about 10 to 20 hectares to support field trials, plant pathogens, entomology, and office space. “Having a research farm allows us to conduct our field work much more efficiently,” says Hopf. “We will have the core competencies to take on external compounds and technologies to onboard them onto our pipeline.”

The expansion will initially support GreenLight’s work in Europe to address crop challenges caused by powdery mildew, botrytis, fusarium, and the Colorado potato beetle.

About GreenLight
Founded in 2008, GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective production of RNA. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq. For more information, visit https://www.greenlightbiosciences.com/.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Thomas Crampton
SVP & Head of Corporate Affairs
GreenLight Biosciences
tcrampton@greenlightbio.com
+44 7826 995794
+1-914-202-2762

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/16f0da58-c98f-4326-9889-0fbc85f238a5

FAQ

What is GreenLight Biosciences' new initiative in Spain?

GreenLight Biosciences has agreed to operate a field research station in Spain to enhance its agricultural research.

How will the field research station benefit GreenLight's projects?

The station will facilitate broad-spectrum testing and support key projects addressing plant diseases and insects.

What specific crop challenges will GreenLight address with the new facility?

GreenLight will focus on issues like powdery mildew, botrytis, fusarium, and the Colorado potato beetle.

What is the significance of the location chosen for the research station?

The station is located south of Seville, a key agricultural area, allowing for intensive year-round production.

What is the ticker symbol for GreenLight Biosciences?

GreenLight Biosciences trades under the ticker symbol GRNA on Nasdaq.